BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wilkins A, Naismith O, Brand D, Fernandez K, Hall E, Dearnaley D, Gulliford S. Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation. International Journal of Radiation Oncology*Biology*Physics 2020;106:928-38. [DOI: 10.1016/j.ijrobp.2020.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Heemsbergen WD, Incrocci L, Pos FJ, Heijmen BJM, Witte MG. Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial. Front Oncol 2020;10:469. [PMID: 32346534 DOI: 10.3389/fonc.2020.00469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Aggarwal A, Nossiter J, Parry M, Sujenthiran A, Zietman A, Clarke N, Payne H, van der Meulen J. Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit. The Lancet Oncology 2021;22:e207-15. [DOI: 10.1016/s1470-2045(20)30558-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Shelley LEA, Sutcliffe MPF, Thomas SJ, Noble DJ, Romanchikova M, Harrison K, Bates AM, Burnet NG, Jena R. Associations between voxel-level accumulated dose and rectal toxicity in prostate radiotherapy. Phys Imaging Radiat Oncol 2020;14:87-94. [PMID: 32582869 DOI: 10.1016/j.phro.2020.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Groen VH, Zuithoff NPA, van Schie M, Monninkhof EM, Kunze-Busch M, de Boer HCJ, van der Voort van Zyp J, Pos FJ, Smeenk RJ, Haustermans K, Isebaert S, Draulans C, Depuydt T, Verkooijen HM, van der Heide UA, Kerkmeijer LGW. Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Radiother Oncol 2021;162:98-104. [PMID: 34214614 DOI: 10.1016/j.radonc.2021.06.033] [Reference Citation Analysis]
5 Braide K, Kindblom J, Lindencrona U, Hugosson J, Pettersson N. Salvage radiation therapy in prostate cancer: relationship between rectal dose and long-term, self-reported rectal bleeding. Clin Transl Oncol 2021;23:397-404. [PMID: 32621207 DOI: 10.1007/s12094-020-02433-4] [Reference Citation Analysis]
6 Spohn SKB, Adebahr S, Huber M, Jenkner C, Wiehle R, Nagavci B, Schmucker C, Carl EG, Chen RC, Weber WA, Mix M, Rühle A, Sprave T, Nicolay NH, Gratzke C, Benndorf M, Wiegel T, Weis J, Baltas D, Grosu AL, Zamboglou C. Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09434-2] [Reference Citation Analysis]
7 Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys 2021;109:174-85. [PMID: 32861817 DOI: 10.1016/j.ijrobp.2020.08.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
8 Schad MD, Patel AK, Ling DC, Smith RP, Beriwal S. Hypofractionated Prostate Radiation Therapy: Adoption and Dosimetric Adherence Through Clinical Pathways in an Integrated Oncology Network. JCO Oncol Pract 2021;17:e537-47. [PMID: 33095692 DOI: 10.1200/OP.20.00508] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Kronborg CJS, Christensen P, Pedersen BG, Spindler KG. Anorectal function and radiation dose to pelvic floor muscles after primary treatment for anal cancer. Radiother Oncol 2021;157:141-6. [PMID: 33545256 DOI: 10.1016/j.radonc.2021.01.027] [Reference Citation Analysis]
10 Bonomo P, Lo Russo M, Nachbar M, Boeke S, Gatidis S, Zips D, Thorwarth D, Gani C. 1.5 T MR-linac planning study to compare two different strategies of rectal boost irradiation. Clin Transl Radiat Oncol 2021;26:86-91. [PMID: 33336086 DOI: 10.1016/j.ctro.2020.11.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Bohoudi O, Bruynzeel AME, Tetar S, Slotman BJ, Palacios MA, Lagerwaard FJ. Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer. Radiother Oncol 2021;157:197-202. [PMID: 33545251 DOI: 10.1016/j.radonc.2021.01.022] [Reference Citation Analysis]
12 Spohn SKB, Sachpazidis I, Wiehle R, Thomann B, Sigle A, Bronsert P, Ruf J, Benndorf M, Nicolay NH, Sprave T, Grosu AL, Baltas D, Zamboglou C. Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference. Front Oncol 2021;11:652678. [PMID: 34055621 DOI: 10.3389/fonc.2021.652678] [Reference Citation Analysis]
13 Ebert MA, Gulliford S, Acosta O, de Crevoisier R, McNutt T, Heemsbergen WD, Witte M, Palma G, Rancati T, Fiorino C. Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations. Phys Med Biol 2021;66. [PMID: 34049304 DOI: 10.1088/1361-6560/ac0681] [Reference Citation Analysis]
14 Cuccia F, Corradini S, Mazzola R, Spiazzi L, Rigo M, Bonù ML, Ruggieri R, Buglione di Monale E Bastia M, Magrini SM, Alongi F. MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. Cancers (Basel) 2021;13:1791. [PMID: 33918650 DOI: 10.3390/cancers13081791] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Zamboglou C, Spohn SKB, Adebahr S, Huber M, Kirste S, Sprave T, Gratzke C, Chen RC, Carl EG, Weber WA, Mix M, Benndorf M, Wiegel T, Baltas D, Jenkner C, Grosu AL. PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. Cancers (Basel) 2021;13:5795. [PMID: 34830950 DOI: 10.3390/cancers13225795] [Reference Citation Analysis]
16 Lapierre A, Hennequin C, Beneux A, Belhomme S, Benziane N, Biston MC, Crehange G, de Crevoisier R, Dumas JL, Fawzi M, Lisbona A, Pasquier D, Pelissier S, Graff-Cailleaud P, Pommier P, Sargos P, Simon JM, Supiot S, Tantot F, Chapet O. Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group. Crit Rev Oncol Hematol 2022;:103661. [PMID: 35341986 DOI: 10.1016/j.critrevonc.2022.103661] [Reference Citation Analysis]
17 Staffurth JN, Haviland JS, Wilkins A, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Birtle A, Malik Z, Panades M, Eswar C, Graham J, Russell M, Ferguson C, O'Sullivan JM, Cruickshank CA, Dearnaley D, Hall E; CHHiP Trial Management Group. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016). Eur Urol Oncol 2021:S2588-9311(21)00145-0. [PMID: 34489210 DOI: 10.1016/j.euo.2021.07.005] [Reference Citation Analysis]
18 Anetai Y, Koike Y, Takegawa H, Nakamura S, Tanigawa N. Evaluation approach for whole dose distribution in clinical cases using spherical projection and spherical harmonics expansion: spherical coefficient tensor and score method. J Radiat Res 2021:rrab081. [PMID: 34590126 DOI: 10.1093/jrr/rrab081] [Reference Citation Analysis]